This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1993 Sep 18;342(8873):693-4.

doi: 10.1016/0140-6736(93)91702-n.

Factor VIII preparations: need for prospective pharmacovigilance

J Vermylen¹, E Briët

Affiliations

PMID: 8103816
DOI: 10.1016/0140-6736(93)91702-n

Comment

Factor VIII preparations: need for prospective pharmacovigilance

J Vermylen et al. Lancet. 1993.

. 1993 Sep 18;342(8873):693-4.

doi: 10.1016/0140-6736(93)91702-n.

Authors

J Vermylen¹, E Briët

Affiliation

¹ Department of Haematology, University of Leiden, Netherlands.

PMID: 8103816
DOI: 10.1016/0140-6736(93)91702-n

No abstract available

PubMed Disclaimer

Comment in

Pharmacovigilance for plasma-derived clotting factor concentrates.
Tagariello G, Cavallin F, Davoli PG, Gajo GB, De Biasi E, Traldi A. Tagariello G, et al. Lancet. 1993 Dec 11;342(8885):1489. doi: 10.1016/0140-6736(93)92967-x. Lancet. 1993. PMID: 7902506 No abstract available.

Comment on

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau TS, Lusher J, et al. Seremetis SV, et al. Lancet. 1993 Sep 18;342(8873):700-3. doi: 10.1016/0140-6736(93)91706-r. Lancet. 1993. PMID: 8103820 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.